Dr Lian, Qizhou 連祺周
Dr Qizhou Lian currently is a practicing Authorized Person (AP) for Advanced Therapy Products (ATP) registered on the Pharmacy & Poisons Board of Hong Kong, and serves as AP/Scientific Officer for the HKUMed Laboratory of Cellular Therapeutics, the first cellular therapy cGMP manufacturing facility in University of Hong Kong (HKU). He also is a Principal Investigator in the State Key Laboratory of Pharmaceutical Biotechnology in HKU, an Honorary Professor in Peking University Shenzhen Hospital and Guangzhou Medical University Women and Children’s Medical Centre.
Dr Lian has more than 20 years of experiences in scientific research, bioprocessing and biomanufacturing development of stem cell- and gene-based therapies. In 2014, he pioneered the Asia’s first hematopoietic stem cell gene therapy and successfully saved patients suffered from metachromatic leukodystrophy (MLD), a rare hereditary disease caused by accumulation of fats in brain called sulfatides. He leads a dynamic interdisciplinary research group in cell and gene therapies that collaborates with academic institutions, industry partners, and leading clinicians in the Guangdong–Hong Kong–Macau Greater Bay Area (GBA). Up to date, he has filed 11 patents and has over 100 peer-reviewed publications. He also has supervised and nurtured over 24 M.Phil./Ph.D. students and Postdoctoral Fellows since 2011.
Dr Lian received his doctoral degree of Medicine (M.D., Ph.D.) from Harbin Medical University in 1999 and was a practicing Cardiologist. Later he was interested in regenerative medicine and spent over 10 years of stem cell research in the Genome Institute of Singapore and Utrecht University Medical Centre Netherlands. He joined HKU as a Research Assistant Professor in 2008 and became Assistant Professor in 2011. In 2018, HKU announced to establish a cellular therapy facility, he resigned his acceptance of Reader (Associate Professor) appointment in the University of Aberdeen UK and joined HKU cellular therapy cGMP manufacturing projects. In 2019-2020 he was a visiting scientist in Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility, systematically involved in stem cell and immune cell cGMP manufacturing projects. He completed Pharmaceutical QP (Qualified Person) training programs held by NSF in UK and holds a Postgraduate Diploma in Pharmaceutical Quality & Good Manufacturing Practice at the University of Strathclyde.
|Awardees||Award Date||Honours / Awards / Prizes||Category|
|2012-06-01||2012 10th Annual ISSCR Travel Grant Award.: International Society of Stem Cell Research(ISSCR). Yokohama, Japan, 13rd-16th, June, 2012." HUMAN IPSC-DERIVED MESENCHYMAL STEM CELLS MODULATE MYOCARDIAL REGENERATION THROUGH REDUCING OXIDATIVE STRESS AND RESTORING CARDIAC PROGENITOR CELLS IN ANTHRACYCLINE CARDIOMYOPATHY”||Research Achievement|
|2014-11-01||Outstanding Oral presentation - Amelioration of cigarette smoke-induced cardiac dysfunction and inflammation by mesenchymal stem cells: 18th Annual Scientific Meeting of Institute of Cardiovascular Science and Medicine||Research Achievement|
|2012-05-01||2012Young Investigator Travel Award: Liver Transplantation|
ISSN: 1527-6465 ; eISSN: 1527-6473
|2014-05-01||Best Abstract - Mitochondrial Transfer Of Human Induced Pluripotent Stem Cells-derived Mesenchymal Stem Cells To Airway Epithelial Cells Attenuates Cigarette Smoke-induced Damage: ATS 2014 International Conference||Research Achievement|
|2015-12-01||Poster Presentation Award at the 20th Research Postgraduate Symposium: The University of Hong Kong, Faculty of Medicine||Research Achievement|
|2014-10-01||3rd Prize for Outstanding Oral Presentation: Journal of the Hong Kong College of Cardiology|
|2007-03-01||Young Investigator Award: Second Symposium on Healthy Aging: Meeting the Challenges of an Aging Population . March 3-4, 2007 ,Hong Kong: Establishing clonal cell lines with endothelial potential from mouse embryonic stem cells||Research Achievement|
|Term Period||Position||Professional Societies|
|02/2012-03/2022||member||International Society of Stem Cell Research (ISSCR)|
|02/2012-03/2022||member||International Society for Stem Cell Research|
|Theme-based Research Scheme(T12-708/12N)||Functional analyses of how genomic variation affects personal risk for degenerative skeletal disorders (Co-PI, grant awarded for 5 yrs 74,553,000HK$)|
|Theme-based Research Scheme(T12-705/11)||Personalized Medicine for Cardiovascular Diseases: From Genomic Testing and Biomarkers to Human Pluripotent Stem Cell Platform( Co-I,grant awarded for 5 yrs 34,944,000HK$)|
Are You Missing Publications, Invited Lectures? Click Me.